TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) › Net IncomeTEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) — Net IncomeAnnual figures by period end, from SEC filings.2007-12-31: $1.91B2008-12-31: $609.00M2009-12-31: $2.00B2010-12-31: $3.33B2011-12-31: $2.76B2012-12-31: $1.96B2013-12-31: $1.27B2016-12-31: $329.00M2017-12-31: -$16.27B2018-12-31: -$2.15B2019-12-31: -$999.00M2020-12-31: -$3.99B2021-12-31: $417.00M2022-12-31: -$2.45B2023-12-31: -$559.00M2024-12-31: -$1.64B2025-12-31: $1.41B$1.41B2007-12-31Net Income (USD)2025-12-31Period endedNet IncomeChange YoYSource filing2025-12-31$1.41B—2026-02-03From 2025-01-012024-12-31-$1.64B—2026-02-03From 2024-01-012023-12-31-$559.00M—2026-02-03From 2023-01-012022-12-31-$2.45B-686.6%2025-02-05From 2022-01-012021-12-31$417.00M—2024-02-12From 2021-01-012020-12-31-$3.99B—2023-02-10From 2020-01-012019-12-31-$999.00M—2022-02-09From 2019-01-012018-12-31-$2.15B—2021-02-10From 2018-01-012017-12-31-$16.27B-5043.8%2020-02-21From 2017-01-012016-12-31$329.00M—2019-02-19From 2016-01-072013-12-31$1.27B-35.4%2014-02-10From 2013-01-012012-12-31$1.96B-28.9%2014-02-10From 2012-01-012011-12-31$2.76B-17.2%2014-02-10From 2011-01-012010-12-31$3.33B+66.5%2013-02-12From 2010-01-012009-12-31$2.00B+228.4%2012-02-17From 2009-01-012008-12-31$609.00M-68.2%2011-02-15From 2008-01-012007-12-31$1.91B—2010-02-22From 2007-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)